NASDAQ: XLO
Xilio Therapeutics Inc Stock Ownership - Who owns Xilio Therapeutics?

Insider buying vs selling

Have Xilio Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
James Samuel ShannonDirector2026-03-265,000$8.79
$43.95kBuy
Kevin M. BrennanSVP FINANCE AND ACCOUNTING2026-01-021,826$0.64
$1.17kSell
Christopher James FrankenfieldChief Financial Officer2026-01-027,030$0.64
$4.52kSell
James Samuel ShannonDirector2025-06-1725,000$0.69
$17.23kBuy
Rene RussoPRESIDENT AND CEO2025-06-1636,289$0.68
$24.68kBuy
James Samuel ShannonDirector2025-06-1645,000$0.69
$30.87kBuy

1 of 1

XLO insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when XLO insiders and whales buy or sell their stock.

XLO Shareholders

What type of owners hold Xilio Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Gilead Sciences Inc157.47%9,105,451$72.12MInsider
Gilead Sciences Inc157.47%9,105,451$72.12MInstitution
Bain Capital Life Sciences Investors LLC127.50%7,372,686$58.39MInstitution
Yekaterina Chudnovsky121.05%7,000,000$55.44MInsider
Frazier Life Sciences Management LP102.29%5,915,091$46.85MInstitution
Point72 Asset Management LP69.17%4,000,000$31.68MInstitution
Sv7 Impact Medicine Fund LP55.81%3,227,264$25.56MInsider
Bain Capital Life Sciences Investors LLC48.52%2,805,413$22.22MInsider
Atlas Venture Fund XI LP47.63%2,754,109$21.81MInsider
James E. Flynn39.57%2,287,944$18.12MInsider

1 of 3

XLO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
XLO53.31%46.69%Net BuyingNet Buying
TELO6.65%46.16%Net BuyingNet Buying
HYPD5.48%94.52%Net Buying
DWTX0.21%76.92%
NTRB2.99%49.04%

Xilio Therapeutics Stock Ownership FAQ

Who owns Xilio Therapeutics?

Xilio Therapeutics (NASDAQ: XLO) is owned by 687.03% institutional shareholders, 601.63% Xilio Therapeutics insiders, and 0.00% retail investors. Gilead Sciences Inc is the largest individual Xilio Therapeutics shareholder, owning 9.11M shares representing 157.47% of the company. Gilead Sciences Inc's Xilio Therapeutics shares are currently valued at $75.76M.

If you're new to stock investing, here's how to buy Xilio Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.